If patients must be coadministered a strong cyp3a4 inducer, based on pharmacokinetic studies, a torisel dose increase from 25 mgweek up to 50 mgweek should be considered. Severe and fatal hemorrhages occurred with cabometyx. For disease that is of nonclear histology, cometriq will be used as firstline systemic therapy. It is a small molecule inhibitor of the tyrosine kinases cmet and vegfr2, and also inhibits axl and ret. The incidence of grade 3 to 5 hemorrhagic events was 5% in cabometyx. Protein in your urine and possible kidney problems. Cabometyx cabozantinib is contraindicated in patients who are. Cabometyx cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib. These tyrosine kinases are involved in both normal cellular function and pathologic processes, such as. Call your doctor for medical advice about side effects. Zivaflibercept acts as a soluble receptor that binds to human vegfa equilibrium dissociation constant kd of 0. Monitor hepatic function prior to and during treatment see warnings and precautions 5. History of serious hypersensitivity reactions, including anaphylaxis, to oncaspar or to any of the excipients.
The clinically important adverse reactions observed in trials comparing plavix plus aspirin to placebo plus aspirin and trials comparing plavix alone to aspirin alone are discussed below. If you have difficulty viewing the document below, please click here to view the full prescribing information, including the boxed warning. Handfoot skin reactions are common with cometriq and can be severe. Cometriq has been shown to inhibit the activity of met. Eocco010 description cabozantinib cabometyx, cometriq is an orally administered tyrosine kinase inhibitor of ret, met. Is caused by a defect in a gene called anaplastic lymphoma kinase alk and has spread to other parts of the body.
Official site for healthcare professionals nexavar. Highlights of prescribing information cardiac dysfunction. Highlights of prescribing information perforation can. Cabometyx cabozantinib tablets and cometriq cabozantinib capsules are not bioequivalent and should not be used interchangeably see section 5. If a patient must switch from cabozantinib capsules to cabozantinib tablets, the patient should continue at a cabometyx dose not to exceed 60 mg or the current cometriq dose whichever is lower. Cometriq increased the incidence of thrombotic events venous thromboembolism. In some cases, health care professionals may use the generic name cabozantinib when referring to the trade name cometriq. Coadministration with a strong cyp3a4 inhibitor increased the exposure of cabozantinib, which may increase the risk of exposurerelated adverse reactions. This medicinal product is subject to additional monitoring.
Accelerated approval was granted for fl and sll based on. Highlights of prescribing information these highlights do. Our cometriq cabozantinib side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Although patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Cometriq cabozantinib capsules are supplied as printed hard gelatin capsules containing cabozantinib smalate equivalent to 20 mg or 80 mg cabozantinib and the following inactive ingredients. Full text the treatment landscape in thyroid cancer. Unresectable locoregional disease that is symptomatic or structurally progressive.
Stivarga regorafenib is a prescription medicine used to treat people with. Do not substitute cabometyx tablets with cabozantinib capsules. The use of concomitant strong cyp3a4 inducers should be avoided e. Cabometyx cabozantinib tablets and cometriq cabozantinib capsules are not. Asymptomatic distant metastases if structurally progressive and unresectable iii. Cometriq cabozantinib is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer mtc. Blinatumomab is a bispecific cd19directed cd3 tcell engager that binds to cd19 expressed on the surface of cells of blineage origin and. Cometriq cabozantinib 100mg dailydose pack 1 dose pack 56 capsules per 28 days cometriq cabozantinib 140mg dailydose pack 1 dose pack 112 capsules per 28 days approval criteria requests for cometriq cabozantinib capsules may be approved if the following criteria are met. Cometriq is the trade name for the generic chemotherapy drug cabozantinib. Your healthcare provider should tell you when you may start taking cabometyx again after surgery. You should stop taking cabometyx at least 3 weeks before planned surgery. It is not known if zykadia is safe and effective in.
Fatal andor serious and severe diarrhea or colitis occurred in 14% to 19% of zydeligtreated patients. Cometriq 20mg gelatin capsules are grey with xl184 20mg printed in black on the body of the capsule. Cabozantin cabometyx, cometriq eocco policy policy type. Tell your healthcare provider right away if you have rashes, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.
Talk to your healthcare provider about the risks and benefits of using this medication when pregnant see cometriq and pregnancy. In 2012 cabozantinib in its capsule formulation was. The active substance in cometriq, cabozantinib, is a tyrosine kinase inhibitor. It is not known if cometriq is safe and effective in children. Cometriq is a prescription medicine used to treat people with medullary thyroid cancer that has spread to other parts of the body. Wound healing problems have happened in some people who take cabometyx. The antiangiogenic ceiling in hepatocellular carcinoma. History of serious thrombosis with prior lasparaginase therapy. It is a medicine used to treat medullary thyroid cancer, a rare type of. Please scroll down to see important safety information for cometriq and click here to see the full prescribing information. Side effects of cometriq cabozantinib capsules, warnings, uses. Cometriq 80mg gelatin capsules are swedish orange with xl184 80mg printed in black on the body of the capsule.
Highlights of prescribing information tafinlar with. Highlights of prescribing information palmarplantar. See full prescribing information for complete boxed warning. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer mtc.
The clinically important adverse reactions observed in trials comparing plavix plus aspirin to placebo plus aspirin and trials comparing plavix alone to. Cabozantinib, sold under the brandname cabometyx and cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. Cometriq is a pregnancy category d medication, which means it may harm an unborn child. Eocco010 description cabozantinib cabometyx, cometriq is an orally administered tyrosine kinase inhibitor of ret, met, vegfr123, kit, trkb, flt3, and tie2. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking cabometyx.
Start with nexavar sorafenib as a foundation for a systemic treatment plan 15. For disease that is of predominantly clear cell histology, cometriq will be used for disease that has progressed on prior antiangiogenic therapy e. The printed package leaflet of the medicinal product must state the name and address of the. Authorization of 24 months may be granted to members prescribed cometriq for medullary thyroid cancer whose disease meets one of the following. Fda grants regular approval to cabometyx for firstline. Cometriq while maintaining optimal therapeutic outcomes.
Cabozantinib smalate salt is a white to offwhite solid that is practically insoluble in aqueous media. Cometriq may react with a number of other medications see cometriq drug interactions. Interrupt and then reduce or discontinue stivarga for hepatotoxicity as manifested by elevated liver. It is an oral receptor tyrosine kinase inhibitor for more detail. Labeling package insert, labelingcontainercarton labels. Tell your healthcare provider if you plan to have any surgery before or during treatment with cabometyx. Cometriq fda prescribing information, side effects and uses. Zykadia is a prescription medicine that is used to treat people with nonsmall cell lung cancer nsclc that. Side effects of cometriq cabozantinib capsules, warnings.
Cometriq is prescribed to treat medullary thyroid cancer in adults. It also offers an explanation of how this drug works. Severe and sometimes fatal hepatotoxicity has occurred in clinical trials. Highlights of prescribing information when administering. Nccn clinical practice guidelines in oncology nonsmall cell lung cancer version 3. This emedtv web page discusses why cometriq is only used when the cancer has progressed to other areas of the body. Cometriq is a cancer medicine that contains the active substance cabozantinib smalate. Highlights of prescribing information perforation can occur. Cometriq, cabometyx cabozantinib dosing, indications. Cometriq is a prescription medicine used to treat people with medullary thyroid cancer mtc that has spread to other parts of the body called metastatic mtc it is not known if cometriq is safe and effective in children. Administration of a strong cyp3a4 inhibitor, ketoconazole to healthy subjects increased singledose plasma cabozantinib exposure by 38% cabometyx. If previously receiving 60 mg daily dose, resume treatment at 40 mg daily. Cometriq cabozantinib is a cancer medicine indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer mtc 1,2. This is not a complete list of side effects and others may occur.
Hepatotoxicity severe and sometimes fatal hepatotoxicity has occurred in clinical trials see warnings and precautions 5. Feb 14, 2020 nearly all cometriq treated patients 96% vs. Unresectable locoregional disease that is symptomatic or structurally progressive ii. Package label carton 100 mg daily dose of cometriq. Highlights of prescribing information these highlights do not. Cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma rcc who have received prior anti angiogenic therapy. Dec 23, 2019 cometriq 20mg gelatin capsules are grey with xl184 20mg printed in black on the body of the capsule. On december 19, 2017, the food and drug administration granted regular approval to cabozantinib cabometyx, exelixis, inc. Cabometyx, inncabozantinib european medicines agency. Please see the accompanying full prescribing information for cometriq. Oncology related including new drugs, antagonists, etc. Do not administer cometriq to patients with a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Oncaspar pegaspargase is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and adult patients with. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
Erivedge vismodegib capsules, for oral use initial u. Carefirst bluecross blueshield is the shared business name of carefirst of maryland, inc. The most common laboratory abnormalities incidence. Monitor for the development of severe diarrhea or colitis. Highlights of prescribing information antiplatelet. Cometriq treatment results in an increased incidence of treatmentemergent hypertension with joint national committee on prevention, detection, evaluation, and treatment of high blood pressure modified jnc criteria stage 1 or 2 hypertension identified in 61% in cometriqtreated patients compared with 30% of placebotreated patients in the randomized trial. Talk to your healthcare provider about the risks and benefits of using this medication when pregnant see. Cometriq cabozantinib capsules 100 mg daily dose blister cards each 100 mg daily dose contains a combination of one swedish orange 80 mg and one grey 20 mg capsule. Coronavirus covid19 update at exelixis, we remain committed to serving the needs of people who take cabometyx.
Gastrointestinal perforations occurred in 3% and fistula formation in 1% of. Cabometyx cabozantinib is indicated for the treatment of patients with. Cabozantinib in patients with advanced and progressing. Coadministration with a strong cyp3a4 inhibitor increased the exposure of cabozantinib, which may increase the.